Cowen & Co.
Cowen Initiates Coverage of NeoGenomics at Outperform
The investment bank said it expects the launch of NeoGenomics' minimal residual disease test will accelerate growth.
Exagen Prices $60.1M Public Offering of Stock
The company said it plans to use the proceeds to develop multiomics capabilities, including building out its clinical laboratory.
Roche to Acquire GenMark Diagnostics for $1.8B
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.
Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider
Illumina thinks the next-generation sequencing cancer testing market will grow to $75 billion over the next 15 years, driven by screening.
Adaptive Biotechnologies to Raise $240M in Public Stock Offering
The offering consists of 8 million shares at an offering price of $40 per share, of which 2 million are being sold by a shareholder.
Jul 9, 2019
Cowen Downgrades Myriad Genetics' Stock
Mar 13, 2019